Market revenue in 2022 | USD 764.0 million |
Market revenue in 2030 | USD 1,385.1 million |
Growth rate | 7.7% (CAGR from 2022 to 2030) |
Largest segment | Software |
Fastest growing segment | Software |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Software, Professional Services |
Key market players worldwide | Elekta AB ADR, Accuray Inc, Siemens Healthineers AG ADR, RaySearch Laboratories AB Class B, Oracle Corp, Koninklijke Philips NV, ViewRay, Hochtief AG, McKesson Corp, BrainLAB, Prowess, Polaris Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology information systems market will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 73.22% in 2022. Horizon Databook has segmented the Europe oncology information systems market based on software, professional services covering the revenue growth of each sub-segment from 2018 to 2030.
Europe oncology information systems is expected to grow at a significant pace in the coming years. The major factor driving the demand in the market is the rise in cancer prevalence in European countries. As per WHO Europe, approximately 3.7 million new cases are diagnosed with cancer and 1.9 million cancer deaths occur every year.
Innovations in the oncology information systems and solutions market will positively impact the market over the years. For instance, Siris Medical deployed artificial intelligence technology in its PlanMD decision support software. This addition aids the radiologist to analyze efforts in real-time contour planning, thereby reducing treatment planning time by 70%.
Laboratories deployed artificial intelligence technology to its TPS 8B software version that automates the treatment planning process and organ segmentation. Furthermore, in January 2018, MIM Software was granted approval from the U.S. FDA for its latest molecular radiotherapy solution, MIM SurePlan RT that uses radiopharmaceuticals for targeting tumor sites.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe oncology information systems market , including forecasts for subscribers. This continent databook contains high-level insights into Europe oncology information systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account